MediciNova

MediciNova, Inc. is a publicly traded biopharmaceutical company focused on the U.S. market, dedicated to the acquisition and development of novel small molecule therapies. MediciNova's current portfolio primarily includes six clinical-stage compounds for the treatment of conditions such as acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Currently, the company’s strategy focuses on its two lead product candidates, MN-221 and MN-166.